What the Health with Emily Casey

In Part Two of my conversation with Dr Steven Lu, Everlab’s co-founder and Chief Medical Officer, we unpack what’s actually worth measuring, which treatments show real promise, what’s still experimental and what the future of preventative healthcare could look like.
And why, when it comes to optimising our health, we should be problem-centric, not solution-centric.

We dive into:
What keeps Steven up at night as Everlab grows and expands internationally.
What’s actually worth measuring: From Lp(a), a genetically influenced cardiovascular risk marker, to body composition, and the tests Steven believes deserve more attention.
GLP-1s, breakthrough drugs or misunderstood medicine? Their potential, the risks of poor dosing and inadequate support, and why protecting muscle and bone health matters.
The peptide boom: What’s backed by evidence, the safety and quality concerns, and why Steven isn’t ready to inject them himself. Yet.
Being problem-centric, not solution-centric: Why chasing the latest tests, treatments and biohacks isn’t necessarily the best approach to better health.
AI and the future of primary care: How Everlab’s Concierge is bringing AI into healthcare while keeping clinicians in the loop.
The next frontier of preventative medicine: Pharmacogenetics, personalised care and emerging Alzheimer’s blood tests.
Hype or worth it? Steven’s rapid-fire take on full-body MRIs, continuous glucose monitors, wearables, NAD+ infusions and creatine, plus the health habits he thinks are overhyped and underappreciated.

Chapters
00:00 Preview: what's real in longevity
01:12 What keeps Steven up at night: leading Everlab through uncharted waters
03:00 What's worth measuring: Lp(a) and body composition
05:28 GLP-1s: what works, and what goes wrong without support
12:13 Peptides: the evidence gap and his "would I take it myself?" test
18:28 Be problem-centric, not solution-centric
22:41 Pharmacogenetics, tailored care and the public system's role
24:03 AI in primary care: keeping a clinician in the loop
27:55 The pTau217 Alzheimer's blood test and what Everlab is studying next
31:06 Rapid fire: MRI, CGMs, wearables, NAD+ and creatine
38:59 Lightning round: favourite emoji, overhyped and underhyped
41:40 Family, where to find Everlab, and thanks

Links and resources
What The Health: https://whatthehealth.io/
Everlab: https://www.everlab.com.au/
Dr Steven Lu at Everlab: https://www.everlab.com.au/doctors
Tenmile Ventures: https://www.tenmile.com/
Mentioned in the episode:
Everlab Concierge product update (the AI health assistant, Eva, that Steven describes): https://www.everlab.com.au/post/introducing-everlab-concierge
KFF Health Tracking Poll, November 2025 (12% of US adults say they currently take a GLP-1 drug; 18% have ever taken one): https://www.kff.org/health-costs/poll-1-in-8-adults-say-they-are-currently-taking-a-glp-1-drug-for-weight-loss-diabetes-or-another-condition-even-as-half-say-the-drugs-are-difficult-to-afford/
TGA, concerns about unapproved peptide products (background to the peptide discussion): https://www.tga.gov.au/news/media-releases/concerns-regarding-public-health-risks-associated-unapproved-peptide-products
RACGP newsGP, TGA warning on unapproved peptides (April 2026): https://www1.racgp.org.au/newsgp/professional/tga-issues-warning-against-unapproved-peptides
MSAC Application 1736 (the proposal to list Lp(a) testing on the MBS; outcome pending): https://www.msac.gov.au/applications/1736
RACGP submission on MSAC Application 1736 (October 2022; opposes the listing): https://www.racgp.org.au/advocacy/reports-and-submissions/view-all-reports-and-submissions/2022-reports-and-submissions/msac-application-1736-lipoprotein-a-testing-as
AusDoc, Australian Atherosclerosis Society backs the proposed Lp(a) MBS items: https://ausdoc.com.au/specialist-update/cardiologists-back-expanded-lipoproteina-testing-for-at-risk-patients
Australian Atherosclerosis Society, patient brochure on elevated lipoprotein(a): https://www.athero.org.au/fh/wp-content/uploads/Lpa-brochure.pdf
Medical Republic on the pTau217 Alzheimer's blood test (Roche test authorised in Australia; the Health Minister's comments): https://medicalrepublic.com.au/mark-butler-and-the-holy-grail-of-dementia-tests/127796
Axios on OpenAI's report on ChatGPT health use (January 2026; more than 40 million people ask daily): https://axios.com/2026/01/05/chatgpt-openai-health-insurance-aca
News 12 New York on the death of a woman after an NAD+ infusion at a Bronx wellness centre (the case Steven refers to in the rapid-fire round): https://bronx.news12.com/prosecutors-unauthorized-nad-iv-infusion-led-to-womans-death

Subscribe for more conversations cutting through the noise in health technology, biotech and healthcare innovation.
What the Health is brought to you in partnership with Tenmile Ventures.
What the Health is part of Day One Network: https://dayone.fm/
#HealthTech #Longevity #PreventativeHealth #AIinHealthcare

Everlab has raised around A$80 million, including a recent A$65 million Series A, reached 20,000 patients and processed more than 21 million biomarker results. Now, after becoming one of Australia’s fastest-growing preventative health companies, it’s taking the model global. (Everlab)
I first spoke to the Everlab team back in 2023. I loved what they were building then, but at the time there were plenty of skeptics about whether this kind of deeply personalised, data-heavy model of preventative healthcare could ever really work at scale.
Three years later, they’re proving that it can.
Longevity has become one of the most hyped corners of healthcare. There’s no shortage of supplements, biohacks, expensive tests and big promises about living longer. But while much of the industry is still selling the idea of longevity, Everlab is turning it into actual healthcare: doctors, diagnostics, longitudinal data, clinical follow-up and preventative care, delivered at increasingly serious scale.
And the company is on a rocket-ship trajectory. Its A$65 million Series A was oversubscribed, it now works with more than 180 clinicians and 1,850 healthcare locations, and it is beginning its push into global markets. (Everlab)
In Part One of this two-part conversation, I sit down with Dr Steven Lu, Everlab’s co-founder and Chief Medical Officer, to unpack how they actually built it, and what it takes to turn the promise of longevity into real-world medicine.
We dive into:
The Everlab journey, from an ambitious idea investors were skeptical of to raising around A$80 million and expanding globally
Why longevity has exploded, and the gap between the hype surrounding the category and what good preventative medicine actually looks like
What the Everlab patient journey actually looks like, and how its model differs from the healthcare most of us experience today
How you take enormous amounts of fragmented health information and turn it into something clinically useful rather than simply giving a pile of test results

Chapters
00:00 Preview: why prevention so often comes too late
01:04 The longevity boom: what's signal and what's expensive theatre
06:22 What "longevity" should mean: healthspan, not hype
10:24 Why prevention still loses to reactive care
17:48 Everlab's model: one plan built from your records
24:26 How AI and clinicians work together on patient data
28:40 The founding team, the mission and the early cases
34:05 Making prevention stick when you feel fine
38:21 Lessons from closing a whole-body MRI business
42:36 Whole-body scans: a great scan, not a magical one
44:39 Patients as customers: trust, Covid and consumer agency
49:46 Where Everlab and preventative care go next

Links and resources
What The Health: https://whatthehealth.io/
Everlab: https://www.everlab.com.au/
Dr Steven Lu at Everlab: https://www.everlab.com.au/doctors
Tenmile Ventures: https://www.tenmile.com/
Mentioned in the episode:
Everlab's Series A announcement (the funding Emily cites): https://www.everlab.com.au/press/everlab-raises-au-65m-series-a-to-make-world-class-preventative-healthcare-something-everyone-can-access
Neko Health's US$700m raise (Emily's reference to a recent whole-body scan raise): https://www.fiercehealthcare.com/health-tech/full-body-scan-startup-neko-health-scores-700m-break-us-market
Australians live longer than previous decades but spend more years in poorer health (MJA InSight+): https://insightplus.mja.com.au/2026/27/australians-live-longer-than-previous-decades-but-spend-more-years-in-poorer-health
National Drug Strategy Household Survey 2022 to 2023 (AIHW; daily smoking is at a record low, while risky drinking is unchanged since 2019): https://www.aihw.gov.au/reports/illicit-use-of-drugs/national-drug-strategy-household-survey-2022-2023/contents/summary
Early-onset bowel cancer research, University of Melbourne: https://about.unimelb.edu.au/news-resources/awards-and-achievements/research-grants-funding/university-of-melbourne-researchers-funded-to-investigate-early-onset-cancer
Search for the causes of rising early-onset bowel cancer, Adelaide University: https://adelaide.edu.au/about/news/2026/search-for-causes-of-rapid-rise-in-bowel-cancer-in-young-people/
Warranty period of coronary CT angiography (European Heart Journal Cardiovascular Imaging, 2023; background to the "warranty" idea Steven describes): https://research.utu.fi/converis/portal/detail/Publication/178099808?lang=en_GB
MoreGoodDays (the digital fibromyalgia program Steven mentions): https://moregooddays.com/

Subscribe for more conversations cutting through the noise in health technology, biotech and healthcare innovation.
What the Health is brought to you in partnership with Tenmile Ventures.
What the Health is part of Day One Network: https://dayone.fm/
#HealthTech #Longevity #PreventativeHealth

A personalised mRNA cancer vaccine has succeeded in a late-stage trial for the first time, and Moderna's shares ripped as much as 177% in a single day on the news. Cancer vaccines have been a graveyard for decades. Something changed.
In the third What the Health Wrap, host Emily Casey is joined by two of her Tenmile colleagues — Dr Joey Man and Dr Michael Lamprecht, investors and scientists with roughly 30 years between them across molecular biology, therapeutics and biotech in the US, Singapore and Australia — for the lunchroom conversation, not the press release.
They start with Moderna and Merck's Phase 3 result. Intismeran autogene, given alongside Keytruda after melanoma surgery, met its primary endpoint of recurrence-free survival and a key secondary endpoint in a trial of more than 1,100 patients. Michael explains what an individualised neoantigen therapy actually is: take a piece of the patient's tumour, work out which signals mark it out from healthy tissue, and turn those into a bespoke vaccine that teaches the immune system what to attack. Joey walks through the part she finds most elegant — an algorithm that reads the patient's normal tissue against their tumour, predicts the mutations a future metastasis would express, picks the top 36, and produces a single-patient batch on a six-to-eight-week timeline deliberately synchronised with the surgery and the standard Keytruda schedule.
The more interesting question is why this one worked when so many didn't. Michael's answer has three parts: it is given in combination with a drug that releases the brake on the immune system, it uses antigens specific to that patient rather than the off-the-shelf antigens that failed before, and — critically — the sponsors got regulators to assess the process rather than each individual antigen. The COVID years, for all the reputational damage they did to mRNA, built the manufacturing infrastructure that makes a one-patient batch possible at all. Joey's read on the share price: a fair reward for patience and a pivot, and a sign that the market has not written off mRNA the way the politics suggested.
From there the conversation turns to the thing Joey is genuinely worried about. From 1 February 2027, Australian reforms will let health technology providers — wearables and monitoring platforms included — collect, use and disclose individual healthcare identifiers with patient consent for permitted purposes. It is close to a world first, and it lands just as a roughly US$44 billion wearables market pushes from wellness towards diagnostics. Joey's objection is not the pipe, it is the water: "just because the pipe is there, it doesn't mean the water quality inside that pipe is good." Storing consumer-sensor data alongside blood work risks lending it a validity it has not earned. Michael pushes back — data is data, sensors improve, and a continuous monitor beats a patient's recollection in a consult. Emily makes the case that a single blood test at a single moment is not the gold standard people assume either, and that longitudinal data is exactly what has been missing.
That tension runs straight into Oura, which is reportedly preparing a US IPO that could value it above US$16 billion while facing a proposed class action over its sleep-tracking claims. Joey is blunt: clinical sleep staging needs EEG, eye movement and muscle movement, and a ring cannot measure EEG. She contrasts the marketed accuracy figure with the 50–53% range she has seen in published work, and notes the awkwardness of defending a 95% claim with "we're not a medical device." Her own ring is a RingConn, bought with expectations set accordingly. Where she does see real progress is in the headband EEG work now being used to track sleep as a treatment-efficacy signal in depression trials.
Then women's health, where the same problem shows up wearing better marketing. Whoop's expanded partnership with Natural Cycles lets overnight skin temperature feed an FDA-cleared contraceptive app — but, as Joey points out, the clearance and the algorithm belong to Natural Cycles, not to Whoop. Oura is building out cycle, pregnancy, postpartum and menopause features. Emily's UltraHuman sends her cycle predictions that are unnervingly accurate, and none of them make the wellness-versus-clinical line any clearer. All three agree the demand is real and long overdue: women have been asking for information about their own bodies that the research never generated.
Joey came to the recording from the Women's Health Foundry investment roundtable, and gives a live read on why the money has been slow. The blockage is upstream — without the research, you cannot define the problem precisely enough to build or fund a solution. Australia produces strong women's health research; the work now is consolidating it into something commercially investable, because commercial dollars move faster than academic ones. Michael's counter is that pharma appetite follows market clarity, not the other way around, and that the market is unambiguously huge. Sun Pharma's roughly US$11.75 billion acquisition of Organon — the women's health business Merck spun out in 2021 — is the proof point.
The last stretch is neuropsychiatry, and Michael's home turf. Eli Lilly has agreed to acquire atai Beckley for US$2.8 billion upfront and up to US$1 billion more in milestones, for a lead programme delivering a short in-clinic psychedelic experience in treatment-resistant depression. Psilocybin and MDMA are both up for approval decisions. Michael explains what a neuroplastogen is — a drug that reopens the brain's ability to rewire, on the theory that depression traps people in a loop they cannot think their way out of — and why he is most interested in the programmes chasing that effect without the trip. Xylo, formerly Psylo, is the Tenmile portfolio company working on exactly that; Michael sits on its board. His prediction: full-day psilocybin protocols will be a niche, because the personnel and infrastructure required cannot compete with a short-acting drug that produces a comparable result.
You'll also hear why Michael thinks AI applied to small molecules is the most underhyped thing in the field, Joey's case for patient-relevant preclinical models replacing animal models in women's health, an unhedged "wearables" when Emily asks what's most overhyped, and a rapid fire that lands on the table-flip emoji, the side eye, the generosity of strangers on the other side of the world, Chopin's Étude No. 5, and two very tired investors who would both quite like some sleep.
Guests
Dr Joey Man Investment Associate, Tenmile Ventures (Melbourne). PhD in Molecular Biology from Monash University's Biomedicine Discovery Institute (breast cancer cell signalling and metastasis); former CSIRO postdoc researching zero-gravity effects on stem cells, with an investing background from Main Sequence Ventures and CSIRO's ON Accelerator.
Dr Michael Lamprecht Investment Manager, Tenmile Ventures (Sydney), specialising in biotech and early-stage investment. PhD in Biomedical Engineering from Columbia University; previously Entrepreneur-in-Residence at Xora Innovation and Director of Regulatory Affairs at EpiBone, with 15+ years building regulatory and clinical strategy for cell-based therapies.
Chapters:
00:00 Cold open
01:03 Welcome and meet the guests
02:59 This fortnight's headlines
04:57 Merck and Moderna's personalised cancer vaccine, explained
11:06 Why working with regulators made this vaccine possible
19:18 Australia's 2027 healthcare identifier reform and the wearables boom
26:38 Oura's sleep-tracking accuracy claims and the class action
30:29 Wearables push into women's health
36:21 Why women's health struggles to attract investment
41:50 Big pharma's next-gen psychiatry bet
51:43 Rapid fire
Links and resources
Merck and Moderna — Phase 3 INTerpath-001 results: https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/
Australia's healthcare identifier reforms, effective 1 February 2027: https://www.minterellison.com/articles/digital-health-reforms-the-regulatory-reform-omnibus-act
Department of Health — Healthcare Identifiers Service: https://www.health.gov.au/topics/health-technologies-and-digital-health/about/healthcare-identifiers
Oura's reported US IPO plans: https://techcrunch.com/2026/08/24/oura-is-reportedly-eyeing-a-september-ipo-that-could-value-it-at-more-than-16b/
Whoop's expanded Natural Cycles partnership:

One in three people will experience a mental health disorder in their lifetime, PTSD went more than 20 years without a new approved treatment, and spending keeps rising while outcomes keep getting worse. Against that backdrop, Australia has become the first country in the world where psychiatrists can prescribe MDMA and psilocybin.
In this episode, host Emily Casey sits down with Dr Michael Winlo, Chief Scientific Officer at Emyria, the company behind the Empax network of psychedelic-assisted therapy clinics. Michael trained as a doctor, spent four years in Palantir's healthcare team in Silicon Valley, then returned to Perth to run a clinical trial site — an experience that convinced him care delivery and evidence generation belong together, and led to Emyria.
Michael explains how the two legal treatments actually work. MDMA floods the brain with serotonin and oxytocin, quietens an overactive amygdala and lets patients with post-traumatic stress disorder work through trauma in therapy without being overwhelmed by fear or shame. Psilocybin quietens the default mode network behind rumination and negative self-talk — Michael's metaphor is shaking up a snow globe and letting the snow settle into new patterns — and both drugs open a roughly seven-day window of heightened neuroplasticity that therapy can use.
The pair trace the strange history that got us here: MDMA first synthesised by Merck in 1912, psychedelics on the cover of psychiatry journals in the 1960s, roughly 500,000 people given MDMA in therapeutic settings before the war on drugs shut the research down. Charitable funding through MAPS kept the science alive, and the resulting phase 2 and 3 trials left the TGA unable to maintain that these drugs had no therapeutic value — leading to the world-first rescheduling in 2023.
Michael then walks through what treatment at an Empax clinic involves: careful screening, a two-therapist dyad that stays with the patient for the whole journey, six-to-eight-hour dosing days in a low-stimulus room, and integration sessions that turn insights into durable habits. Emyria has now treated more than 100 patients, with rapid improvement that appears durable for most — results that have brought funders like Medibank and the Department of Veterans' Affairs on board.
The conversation closes on what it will take to make this mainstream: health-economic evidence for a treatment that costs around $10,000 a dosing cycle, the watershed of a first FDA approval, more sensible regulation of who can deliver therapy, and the infrastructure and training to meet demand. Michael argues psychedelics are still under-hyped — used today as a last resort when they may do the most good earlier in a patient's journey — and leaves clinicians with one message: learn with your patients.
Guest
Dr Michael Winlo is Chief Scientific Officer at Emyria, the ASX-listed company behind the Empax network of psychedelic-assisted therapy clinics, treating post-traumatic stress disorder and treatment-resistant depression under the TGA's Authorised Prescriber Scheme. Trained as a medical doctor, he spent four years in Palantir's healthcare team in Silicon Valley and led Perth's Linear Clinical Research before joining Emyria to build a model of care that treats patients and generates evidence at the same time.
Chapters
00:00 Psychedelics return to healthcare
00:57 What Emyria and the Empax clinics do
02:08 From medicine to Palantir and back to Perth
08:32 Why mental health care is falling behind
12:37 What psychedelics actually are
13:55 How MDMA-assisted therapy works
17:44 Psilocybin and the default mode network
21:05 A century of history: from Merck to the war on drugs
24:18 The revival: MAPS, new trials and Australia's rescheduling
27:17 Why psychiatry innovates slowly
29:47 Inside treatment: screening, dosing days and integration
33:33 The data so far: 100+ patients, Medibank and the DVA
35:18 Ketamine and the coming wave of new treatments
36:47 FDA approval and the funding shift
43:30 Emyria's ten-year vision
45:47 Bottlenecks: training, regulation and infrastructure
47:31 Psychedelic therapy in 2035
49:09 Rapid fire: hype, books and one message for clinicians
Links and resources
Emyria: https://emyria.com/
Empax Centre: https://empaxcentre.com/
TGA — re-scheduling of psilocybin and MDMA, questions and answers: https://www.tga.gov.au/resources/publication/scheduling-decisions-final/notice-final-decision-amend-or-not-amend-current-poisons-standard-june-2022-acms-38-psilocybine-and-mdma/re-scheduling-psilocybin-and-mdma-poisons-standard-questions-and-answers
MAPS (Multidisciplinary Association for Psychedelic Studies): https://maps.org/
COMPASS Pathways: https://compasspathway.com/
The Beginning of Infinity by David Deutsch: https://en.wikipedia.org/wiki/The_Beginning_of_Infinity
Moonshots with Peter Diamandis: https://www.diamandis.com/podcast
About the host
Emily Casey is the founder of What the Health and host of the show, making major developments in health technology and innovation easier to understand.
What the Health is brought to you in partnership with Tenmile Ventures.
What the Health is part of Day One Network, the podcast and media network from W2D1 Media: https://dayone.fm/

A survey of more than 1,800 clinicians across 25 countries found 83% had already adopted AI before their workplace had any governance in place. Healthcare, it turns out, is not just adopting AI. It is being redesigned around it.
In the second What the Health Wrap, host Emily Casey is joined by Dr Simon Kos, Global Chief Medical Officer at Heidi, and Dr Janice Tan, GP and General Manager of Clinical Innovation at Bupa, to work through what the fortnight's biggest healthcare stories actually mean.
Simon uses Heidi's Pressure Points report to bust some long-held myths. Clinicians are not Luddites; get product-market fit right and they will adopt ahead of their own organisations. Product-led growth is not impossible in healthcare. And the idea that everything must run through a single electronic medical record screen does not survive contact with the reality of shadow AI. Janice agrees, arguing that GPs are among the most innovative professionals there are, and that what matters is not clicks or screens but the value exchange.
The conversation turns to where this leaves general practice. Both guests expect voice to become the default way information is entered within two years, freeing clinicians for deeper, more present consultations rather than merely shorter ones. Janice makes the point that scribes save time not to compress the visit but to enrich it. Simon argues that scribes should be commoditised, because they are the entry point to something bigger: infusing evidence and decision support into the flow of care.
They also examine what happens when patients bring their own AI into the room. OpenAI's launch of Health in ChatGPT, and the broader move by frontier labs into consumer health, could be the single biggest driver of health equity, filling the gap for people who previously had no care at all. But Simon draws a firm line between consumer-grade and clinical-grade health, pointing to the liability caps some providers attach to their advice and the accountability the medical profession is held to. The regulatory framework for quality and safety is not yet in place, but it is coming fast.
Janice explains Bupa's own metamorphosis from health insurer to health organisation, investing heavily in primary and preventive care across medical, dental, optical and psychology clinics, and rolling out AI scribes to its clinicians under strong governance. Simon zooms out to a health system whose old boundaries between payer, provider, acute, primary and consumer care are blurring, driven by digital capability, policy reform and a wave of consolidation.
The panel closes on the future of care. They discuss how to equip the next generation of doctors without letting AI become a crutch that erodes clinical judgement, what digital health's US$7.4 billion funding rebound says about capital concentrating into a handful of mega rounds, and why the companies winning big are the ones co-designing with clinicians from day one. Then they imagine the patient journey in 2035, from wellness chairs in autonomous vehicles to consultations that feel, as Janice puts it, more human.
Guests
Dr Simon Kos is Global Chief Medical Officer at Heidi, the AI clinical documentation company. A physician who practised critical care medicine before moving into digital health, he was previously Global Chief Medical Officer at Microsoft and CEO of Next Practice, and is a long-standing figure in Australian digital health.
Dr Janice Tan is a GP and the General Manager of Clinical Innovation at Bupa, where she leads the rollout and piloting of AI solutions across the group's health services. She also advises the RACGP and works to uplift the digital health capability of the GP profession.
Chapters
00:00 Introducing the What the Health Wrap
00:07 Guest updates: Heidi's global expansion and life in general practice
03:03 The fortnight's five biggest headlines
05:11 Heidi's Pressure Points report: adopting AI ahead of governance
06:16 Busting the myths about clinicians and technology
10:11 Where general practice is heading: voice by default and deeper consults
13:00 Patients are bringing their own AI to the consult
14:21 Health in ChatGPT and big tech's move into consumer health
18:33 Consumer-grade versus clinical-grade care and the regulation gap
23:41 Bupa's shift from health insurer to health company
30:29 Training the next generation without de-skilling
33:43 Digital health's US$7.4 billion funding landscape
35:31 Finding the wedge: co-designing with clinicians
38:46 The 2035 patient journey
42:46 Rapid fire: emojis, surprises and companies to watch
Links and resources
Heidi
Heidi's Pressure Points 2026 report
Bupa Australia
Bupa's Connected Care strategy
Bupa to acquire Partnered Health Group
Health in ChatGPT
Rock Health H1 2026 funding and market overview
Australia's ban on genetic discrimination in life insurance
Claude for Healthcare

About the host
Emily Casey is the founder of What the Health and host of the What the Health Wrap, making major developments in health technology and innovation easier to understand.
The What the Health Wrap is brought to you by What the Health in partnership with Tenmile Ventures.
What the Health is part of Day One Network, the podcast and media network from W2D1 Media.